• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Crown Bioscience Oncology Center in San Diego expands services

Crown Bioscience Oncology Center in San Diego expands services

August 17, 2016
CenterWatch Staff

Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has expanded its oncology services with new models, cell lines and assays at its Center of Excellence for Oncology in San Diego.

The new services introduce a range of platforms for the evaluation of immuno-oncology programs, while also adding new technologies for traditional oncology agents. Responding to the global focus on immuno-oncology, CrownBio has added a broad portfolio of highly characterized syngeneic in vivo services, and at the same time expanded its flow cytometry laboratories to support both syngeneic and humanized PDX studies.

Mike Prosser, CrownBio’s general manager of European and North American operations, commenting on the recently announced site expansion and new offering, said, “Following the recent investment in our U.S. site, we now have the capability to offer a significantly extended range of services, from in vitro screening to later stage translational studies, including avatar clinical trials (HuTrials™) with Humanized NSG™ xenografts to evaluate the efficacy of anticancer immunotherapy before entering the clinic.”

CrownBio has also developed new PDX derived cell lines to enrich the company’s PrimePanel™ collection with primary cells from Caucasian, pretreated and metastatic tumor samples to help evaluate traditional oncology agents. Additionally, CrownBio has developed expanded 3D-tumor growth assays (3D-TGA) for most indications to provide translational in vitro models aligned to the tumor microenvironment.

“These new services will allow us to provide our clients, leading global biopharmaceutical companies, with local access to a range of platforms, including advanced models that more accurately reflect tumor microenvironments, thereby offering better screening tools for evaluating innovative oncology drug candidates,” said Jean-Pierre Wery, Ph.D., CEO of CrownBio.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing